Webinar: New Ways of Evaluating the Tumor Immune Microenvironment-1

T-cell redirecting therapies with gene-engineered CAR T-cells and T-cell engaging bispecific antibodies (bsAb) are showing promising results in clinical trials. To guide precision immunotherapy, other factors should also be taken into consideration, including greater availability of immune targets and compounds with different modes of action during the development of new biomarkers, and determinants of response and resistance to a specific regimen. https://www.creative-biolabs.com/bsab/new-ways-of-evaluating-the-tumor-immune-microenvironment-from-bench-to-bedside.html